Jump to ContentJump to Main Navigation
Integrative Neuroscience and Personalized Medicine$
Users without a subscription are not able to see the full content.

Evian Gordon, MD, PhD and Stephen Koslow, PhD

Print publication date: 2010

Print ISBN-13: 9780195393804

Published to Oxford Scholarship Online: January 2011

DOI: 10.1093/acprof:oso/9780195393804.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2017. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in OSO for personal use (for details see http://www.oxfordscholarship.com/page/privacy-policy).date: 12 December 2017

Theranostics and Translation toward Personalized Medicine for Multiple Sclerosis

Theranostics and Translation toward Personalized Medicine for Multiple Sclerosis

Chapter:
(p.205) Theranostics and Translation toward Personalized Medicine for Multiple Sclerosis
Source:
Integrative Neuroscience and Personalized Medicine
Author(s):

Ariel Miller

Tamar Paperna

Opher Caspi

Izabella Lejbkowicz

Elsebeth Staun-Ram

Nili Avidan

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780195393804.003.0011

Recently, medicine began moving to more informed healthcare management and medical treatment guided by diagnostics, termed, theranostics. In the last decade, the search for markers for disease subtypes and more personalized treatment responses has been accelerated by academic researchers and pharmaceutical companies. Currently used high-throughput genome-wide methodology is resulting in a shift to a hypothesis-free approach to identify appropriate genes. This, in turn, has resulted in the identification of a multitude of biomarker candidates that explain a small fraction of patients’ variations in drug response therapy or disease clinical course. These research initiatives need to be followed by functional studies to determine the molecular mode of action and clinical utility of these markers. Here, the status of identification of biomarkers for diagnosis, disease course, treatment response, and related factors involved in development and response to treatment for multiple sclerosis are reviewed.

Keywords:   Multiple sclerosis, biomarkers, pharmacogenetics, theranostics, interferon beta, GWAS, microarray

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .